{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:03:31Z","timestamp":1772463811397,"version":"3.50.1"},"reference-count":160,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharm. Pat. Anal."],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.4155\/ppa.14.22","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T16:40:07Z","timestamp":1412700007000},"page":"429-447","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Advances in Recent Patent and Clinical Trial Drug Development for Alzheimer\u2019s Disease"],"prefix":"10.1080","volume":"3","author":[{"given":"Haibin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy NIDA Center of Excellence for Computational Drug Abuse Research Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"},{"name":"Guangzhou Quality R&D Center of Traditional Chinese Medicine Guangdong Key Laboratory of Plant Resources School of Life Science Sun Yat-Sen University\rGuangzhou\rPR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy NIDA Center of Excellence for Computational Drug Abuse Research Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Su","sequence":"additional","affiliation":[{"name":"Guangzhou Quality R&D Center of Traditional Chinese Medicine Guangdong Key Laboratory of Plant Resources School of Life Science Sun Yat-Sen University\rGuangzhou\rPR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Qun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences Computational Chemical Genomics Screening Center School of Pharmacy NIDA Center of Excellence for Computational Drug Abuse Research Drug Discovery Institute University of Pittsburgh\rPittsburgh\rPA\r15260\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,10,7]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0909142"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.01.010"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(91)90052-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02621"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90609-V"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1991.tb00671.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720508786898451"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.2.137"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.11.010"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2012.01307.x"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.4.558"},{"issue":"1","key":"e_1_3_3_13_1","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"25","author":"Birks J","year":"2006","unstructured":"Birks J . Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst. Rev.25 (1), CD005593 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"e_1_3_3_14_1","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","volume":"25","author":"Birks J","year":"2006","unstructured":"Birks J Harvey RJ . Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst. Rev.25 (1), CD001190 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000213804.59187.2d"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013128"},{"key":"e_1_3_3_17_1","unstructured":"Debiopharm SA. Switzerland: WO2009120774A2 (2009)."},{"key":"e_1_3_3_18_1","unstructured":"The General Hospital Corporation USA; National Institute of Aging Office of Technology Transfer National Institutes of Health: WO2010117727A2 (2010)."},{"key":"e_1_3_3_19_1","unstructured":"Galantos Pharma GmbH Germany : WO2009127218A1 (2009)."},{"key":"e_1_3_3_20_1","unstructured":"Consejo Superior de Investigaciones Cientificas CSIC Spain; Universidad Autonoma de Madrid UAM : WO2011051535A1 (2011)."},{"key":"e_1_3_3_21_1","unstructured":"Teva Pharmaceutical Industries Ltd Israel : US20070232691A1 (2007)."},{"key":"e_1_3_3_22_1","unstructured":"Solvay Pharmaceuticals BV Netherlands: WO2007128674A2 (2007)."},{"key":"e_1_3_3_23_1","unstructured":"Envivo Pharmaceuticals Inc. USA:WO2013169646A1 (2013)."},{"key":"e_1_3_3_24_1","unstructured":"Niconovum USA Inc. USA : US20110274628A1 (2011)."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2013.7"},{"issue":"4","key":"e_1_3_3_26_1","first-page":"P85","article-title":"Results of a double-blind Phase 2b study of monthly mimopezil implants compared with oral donepezil in patients with moderate Alzheimer\u2019s disease (BRAINZ study)","volume":"5","author":"Wilkinson D","year":"2009","unstructured":"Wilkinson D Cohen S Inglis F et al. Results of a double-blind Phase 2b study of monthly mimopezil implants compared with oral donepezil in patients with moderate Alzheimer\u2019s disease (BRAINZ study). Alzheimers Dement.5 (4), P85 (2009).","journal-title":"Alzheimers Dement."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-101311"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-009-9269-5"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945012799499794"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113712"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-002-0025-3"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.10.024"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0594.2011.00827.x"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-9S317"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr3000994"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.65041431.x"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04533"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3647-11.2011"},{"issue":"4","key":"e_1_3_3_40_1","first-page":"P583","article-title":"BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)","volume":"8","author":"Martenyi F","year":"2012","unstructured":"Martenyi F Dean RA Lowe S et al. BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimers Dement.8 (4), P583\u2013P584 (2012).","journal-title":"Alzheimers Dement."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.05.1900"},{"key":"e_1_3_3_42_1","unstructured":"Pfizer Inc. USA : WO2012172449A1 (2012)."},{"key":"e_1_3_3_43_1","unstructured":"Rinat Neuroscience Corp. USA: WO2004032868A2"},{"key":"e_1_3_3_44_1","unstructured":"GlaxoSmithKline Biologicals SA Belgium Affiris AG: WO2013148851A1 (2013)."},{"key":"e_1_3_3_45_1","unstructured":"Eli Lilly and Co. USA:WO2011005738A1 (2011)."},{"key":"e_1_3_3_46_1","unstructured":"Eli Lilly and Co. USA:WO2009134617A1 (2009)."},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","unstructured":"Schering Corp. USA : US20070287692A1 (2007).","DOI":"10.1016\/S1365-6937(07)70189-2"},{"key":"e_1_3_3_48_1","unstructured":"Eli Lilly and Co. USA : US20070299053A1 (2007)."},{"key":"e_1_3_3_49_1","unstructured":"Bristol-Myers Squibb Co. USA : US20100260837A1 (2010)."},{"key":"e_1_3_3_50_1","unstructured":"Waratah Pharmaceuticals Inc. Can: US20100105631 A1 (2010)."},{"key":"e_1_3_3_51_1","unstructured":"Wyeth John and Brother Ltd USA : WO2009089237A1 (2009)."},{"key":"e_1_3_3_52_1","unstructured":"Pfizer Inc. USA : US20050215610A1 (2005)."},{"key":"e_1_3_3_53_1","unstructured":"Elan Pharmaceuticals Inc. USA:US20080045499 A1 (2008)."},{"key":"e_1_3_3_54_1","unstructured":"Chiesi Farmaceutici SpA Italy : WO2011015287A2 (2011)."},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","unstructured":"Schering Corp. USA : US20110027264 A1 (2011).","DOI":"10.1016\/S1359-6128(11)70112-4"},{"key":"e_1_3_3_56_1","unstructured":"Pfizer Inc. USA : WO2012131539A1 (2012)."},{"key":"e_1_3_3_57_1","unstructured":"EnVivo Pharmaceuticals Inc. USA:US20130165486 A1 (2013)."},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0099-3"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/19083"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3365"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210951"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.199356"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0005-x"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.2194"},{"issue":"4","key":"e_1_3_3_65_1","first-page":"e28","article-title":"Nic5\u201315: a novel natural gamma-secretase inhibitor that attenuates brain beta-amyloid content and improves cognition","volume":"5","author":"Pasinetti G","year":"2009","unstructured":"Pasinetti G Rosen Z Grossman H . Nic5\u201315: a novel natural gamma-secretase inhibitor that attenuates brain beta-amyloid content and improves cognition. Alzheimers Dement.5 (4), e28 (2009).","journal-title":"Alzheimers Dement."},{"issue":"4","key":"e_1_3_3_66_1","first-page":"P259","article-title":"NIC5\u201315 as a treatment for Alzheimer\u2019s: safety, pharmacokinetics and clinical variables","volume":"5","author":"Grossman H","year":"2009","unstructured":"Grossman H Marzloff G Luo X Leroith D Sano M Pasinetti G . NIC5\u201315 as a treatment for Alzheimer\u2019s: safety, pharmacokinetics and clinical variables. Alzheimers Dement.5 (4), P259 (2009).","journal-title":"Alzheimers Dement."},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.152975"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167379"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.11.015"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63380-4.00003-2"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00097.x"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.2174\/13892037113149990144"},{"issue":"4","key":"e_1_3_3_73_1","first-page":"S242","article-title":"E2012: a novel gamma-secretase modulator-pharmacology part","volume":"6","author":"Hashimoto T","year":"2010","unstructured":"Hashimoto T Ishibashi A Hagiwara H Murata Y Takenaka O Miyagawa T . E2012: a novel gamma-secretase modulator-pharmacology part. Alzheimers Dement.6 (4), S242 (2010).","journal-title":"Alzheimers Dement."},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/cb400080f"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2006.02.015"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2011.20612"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-394816-8.00006-4"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2008-15207"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.06.018"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12178"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.06.018"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70167-4"},{"key":"e_1_3_3_83_1","unstructured":"Cytokine Pharmasciences Inc. : US20080096909 A1 (2008)."},{"key":"e_1_3_3_84_1","unstructured":"Almqvist Fredrik Sweden : WO2009134203A1 (2009)."},{"key":"e_1_3_3_85_1","unstructured":"Neuropore Therapies Inc. USA : WO2013134371A1 (2013)."},{"key":"e_1_3_3_86_1","unstructured":"Bellus Health Limited Switzerland:WO2010054485A1 (2010)."},{"key":"e_1_3_3_87_1","unstructured":"Elan Pharmaceuticals Inc. USA:WO2012173808A1 (2012)."},{"key":"e_1_3_3_88_1","unstructured":"Prana Biotechnology Ltd Australia : WO2008074068A1 (2008)."},{"key":"e_1_3_3_89_1","unstructured":"Prana Biotechnology Ltd Australia:WO2010071944A1 (2010)."},{"key":"e_1_3_3_90_1","unstructured":"Max-Delbruck-Centrum Fur Molekulare Medizin Germany:US20090117040 A1 (2009)."},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70140-0"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703137104"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.013"},{"issue":"4","key":"e_1_3_3_95_1","first-page":"S142","article-title":"A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of a beta peptide species","volume":"6","author":"Savage MJ","year":"2010","unstructured":"Savage MJ Wu G Mccampbell A et al. A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of a beta peptide species. Alzheimers Dement.6 (4), S142 (2010).","journal-title":"Alzheimers Dement."},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4933-10-18"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.493872"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-013-0002-2"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.578573"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110869"},{"key":"e_1_3_3_101_1","article-title":"Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer\u2019s disease","volume":"11","author":"McCleery J","year":"2012","unstructured":"McCleery J Molena EJ Worrall RE . Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer\u2019s disease. Cochrane Database System. Rev.11, CD010188 (2012).","journal-title":"Cochrane Database System. Rev."},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110977"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4742-11.2012"},{"key":"e_1_3_3_104_1","unstructured":"Cytos Biotechnology AG Switz.; Novartis Pharma AG: WO2004016282A1 (2004)."},{"key":"e_1_3_3_105_1","unstructured":"Janssen Alzheimer Immunotherapy Ireland: US20120276116 A1 (2012)."},{"key":"e_1_3_3_106_1","unstructured":"Merck & Co. Inc. USA:WO2006121656A2 (2006)."},{"key":"e_1_3_3_107_1","unstructured":"AC Immune SA Switzerland; Genentech Inc .: WO2008156622A1 (2008)."},{"key":"e_1_3_3_108_1","unstructured":"United Biomedical Inc. USA : US20110070255 A1 (2011)."},{"key":"e_1_3_3_109_1","unstructured":"Elan Pharma International Ltd Ireland; Wyeth John and Brother Ltd: O2009017467A1 (2009)."},{"key":"e_1_3_3_110_1","unstructured":"Washington University USA; Eli Lilly and Co. : US20110158986 A1 (2011)."},{"key":"e_1_3_3_111_1","doi-asserted-by":"crossref","unstructured":"Rinat Neuroscience Corp. USA:WO2004032868A2 (2004).","DOI":"10.1016\/S1359-6128(04)00126-0"},{"key":"e_1_3_3_112_1","unstructured":"GlaxoSmithKline Biologicals SA Belgium; Affiris AG : WO2013020722A2 (2013)."},{"key":"e_1_3_3_113_1","unstructured":"F. Hoffmann-La Roche AG Switzerland; MorphosysImmune AG: US20130136747 A1 (2013)."},{"key":"e_1_3_3_114_1","unstructured":"AC Immune SA Switzerland; Genentech Inc .: WO2012016173A2 (2012)."},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802611794072605"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200108057"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.3.631"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2111"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4321-06.2007"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.306472"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-120805"},{"key":"e_1_3_3_122_1","unstructured":"Noscira SA Spain; The University of Queensland : WO2013167635A1 (2013)."},{"key":"e_1_3_3_123_1","unstructured":"Noscira SA Spain : WO2013149976A1 (2013)."},{"key":"e_1_3_3_124_1","unstructured":"Consejo Superior de Investigaciones Cientificas CSIC Spain : WO2012113967 A1 (2012)."},{"issue":"4","key":"e_1_3_3_125_1","first-page":"P74","article-title":"Rember. Issues in design of a Phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer\u2019s disease","volume":"5","author":"Wischik C","year":"2009","unstructured":"Wischik C . Rember. Issues in design of a Phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer\u2019s disease. Alzheimers Dement.5 (4 Suppl.), P74 (2009).","journal-title":"Alzheimers Dement."},{"key":"e_1_3_3_126_1","unstructured":"Universidad de Chile Chile:WO2011134098 A1 (2011)."},{"key":"e_1_3_3_127_1","unstructured":"Pharma Eight Co. Ltd Japan: WO2012141228A1 (2012)."},{"key":"e_1_3_3_128_1","unstructured":"University of South Florida USA:WO2013152350A1 (2013)."},{"key":"e_1_3_3_129_1","unstructured":"Neuropharma SA Spain; Noscira SA USA: 20090233971A1 (2009)."},{"key":"e_1_3_3_130_1","unstructured":"WisTa Laboratories Ltd Singapore:WO2012107706A1 (2012)."},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.10.015"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.164491"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-120310"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.92"},{"issue":"1","key":"e_1_3_3_135_1","first-page":"80","article-title":"Latrepirdine, a potential novel treatment for Alzheimer\u2019s disease and Huntington\u2019s chorea","volume":"11","author":"Sabbagh MN","year":"2010","unstructured":"Sabbagh MN Shill HA . Latrepirdine, a potential novel treatment for Alzheimer\u2019s disease and Huntington\u2019s chorea. Curr. Opin. Investig. Drugs11 (1), 80\u201391 (2010).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_3_136_1","unstructured":"Pfizer Inc. USA; Medivation Neurology Inc .: WO2011039675A2 (2011)."},{"key":"e_1_3_3_137_1","unstructured":"Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Israel; Bar Ilan University : WO2013150529A2 (2013)."},{"key":"e_1_3_3_138_1","unstructured":"Ampere Life Sciences Inc .: US20130267538 A1 (2013)."},{"key":"e_1_3_3_139_1","unstructured":"Edison Pharmaceuticals Inc. USA : US20130289034 A1 (2013)."},{"key":"e_1_3_3_140_1","unstructured":"Edison Pharmaceuticals Inc. USA : WO2012174286A1 (2012)."},{"key":"e_1_3_3_141_1","unstructured":"Sanofi France:WO9925363A1 (1999)."},{"key":"e_1_3_3_142_1","unstructured":"Senju Pharmaceutical Co. Ltd Japan; Astellas Pharma Inc. : WO2008133198A1 (2008)."},{"key":"e_1_3_3_143_1","unstructured":"Toyama Chemical Co. Ltd Japan : WO2009145171A1 (2009)."},{"key":"e_1_3_3_144_1","unstructured":"Sanofi-Aventis France : US20130303520 A1 (2013)."},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2006.1894"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1912"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.4.612"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.10.022"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8957"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.20281"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.03.091"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-10-r148"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20248"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.12.067"},{"key":"e_1_3_3_155_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049112h"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2013.03.019"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867311320130008"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9449-z"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci100399j"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci500004h"},{"issue":"3","key":"e_1_3_3_161_1","first-page":"1","article-title":"Chemogenomics knowledge based polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands","volume":"5","author":"Xie X","year":"2014","unstructured":"Xie X Wang L Liu H Ouyang Q Fang C Su W . Chemogenomics knowledge based polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands. Front. Pharmacol.5 (3), 1\u201311 (2014).","journal-title":"Front. Pharmacol."}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa.14.22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:10:59Z","timestamp":1715965859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/ppa.14.22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":160,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.4155\/ppa.14.22"],"URL":"https:\/\/doi.org\/10.4155\/ppa.14.22","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-10-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}